drugset / Trial / NCT00647192
EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion
Phase 2
Terminated
38 enrolled
University Hospital, Saarland
Pfizer · collabUniversity Medical Center Groningen · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this study is to determine whether Eplerenone reduces atrial fibrillation (AF) recurrences within the first 8 weeks after electrical cardioversion of persistent AF.
Timeline
- Start
- 2008-03
- Primary completion
- 2012-02
- Completion
- 2012-02
Outcome
Outcome not reported
Stopped (Enrollment): “Inclusion rate too low. Recruitment of further study centers too costly.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Eplerenone | Unknown | 50 mg | — |